These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 31486978)

  • 41. Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer.
    Panni RZ; Sanford DE; Belt BA; Mitchem JB; Worley LA; Goetz BD; Mukherjee P; Wang-Gillam A; Link DC; Denardo DG; Goedegebuure SP; Linehan DC
    Cancer Immunol Immunother; 2014 May; 63(5):513-28. PubMed ID: 24652403
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hyaluronic Acid-Based Multilayer Films Regulate Hypoxic Multicellular Aggregation of Pancreatic Cancer Cells with Distinct Cancer Stem-Cell-like Properties.
    Lee IC; Wu YC; Hung WS
    ACS Appl Mater Interfaces; 2018 Nov; 10(45):38769-38779. PubMed ID: 30395429
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel therapeutic targets for pancreatic cancer.
    Tang SC; Chen YC
    World J Gastroenterol; 2014 Aug; 20(31):10825-44. PubMed ID: 25152585
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Concomitant targeting of multiple key transcription factors effectively disrupts cancer stem cells enriched in side population of human pancreatic cancer cells.
    Wang X; Liu Q; Hou B; Zhang W; Yan M; Jia H; Li H; Yan D; Zheng F; Ding W; Yi C; Hai Wang
    PLoS One; 2013; 8(9):e73942. PubMed ID: 24040121
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Pancreatic cancer stem cell].
    Hamada S; Masamune A; Shimosegawa T
    Nihon Rinsho; 2015 May; 73(5):844-9. PubMed ID: 25985641
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Heterogeneity and targeting of pancreatic cancer stem cells.
    Penchev VR; Rasheed ZA; Maitra A; Matsui W
    Clin Cancer Res; 2012 Aug; 18(16):4277-84. PubMed ID: 22896694
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression of cancer stem cell markers in pancreatic intraepithelial neoplasias and pancreatic ductal adenocarcinomas.
    Kure S; Matsuda Y; Hagio M; Ueda J; Naito Z; Ishiwata T
    Int J Oncol; 2012 Oct; 41(4):1314-24. PubMed ID: 22824809
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Therapeutic targeting of pancreatic cancer stem cells by dexamethasone modulation of the MKP-1-JNK axis.
    Suzuki S; Okada M; Sanomachi T; Togashi K; Seino S; Sato A; Yamamoto M; Kitanaka C
    J Biol Chem; 2020 Dec; 295(52):18328-18342. PubMed ID: 33115754
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Curcumin attenuates resistance to irinotecan via induction of apoptosis of cancer stem cells in chemoresistant colon cancer cells.
    Su P; Yang Y; Wang G; Chen X; Ju Y
    Int J Oncol; 2018 Sep; 53(3):1343-1353. PubMed ID: 29956726
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discovery of VEGFR-2 inhibitors exerting significant anticancer activity against CD44+ and CD133+ cancer stem cells (CSCs): Reversal of TGF-β induced epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma.
    Modi SJ; Kulkarni VM
    Eur J Med Chem; 2020 Dec; 207():112851. PubMed ID: 33002846
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evolving Strategies for Therapeutically Targeting Cancer Stem Cells.
    Talukdar S; Emdad L; Das SK; Sarkar D; Fisher PB
    Adv Cancer Res; 2016; 131():159-91. PubMed ID: 27451127
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target.
    Yan Y; Zuo X; Wei D
    Stem Cells Transl Med; 2015 Sep; 4(9):1033-43. PubMed ID: 26136504
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
    Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
    Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancer.
    Zhou P; Li B; Liu F; Zhang M; Wang Q; Liu Y; Yao Y; Li D
    Mol Cancer; 2017 Feb; 16(1):52. PubMed ID: 28245823
    [TBL] [Abstract][Full Text] [Related]  

  • 55. ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4.
    Zhou T; Liu J; Xie Y; Yuan S; Guo Y; Bai W; Zhao K; Jiang W; Wang H; Wang H; Zhao T; Huang C; Gao S; Wang X; Yang S; Hao J
    Gut; 2022 Feb; 71(2):357-371. PubMed ID: 33674341
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cancer Stem Cell Markers in Relation to Patient Survival Outcomes: Lessons for Integrative Diagnostics and Next-Generation Anticancer Drug Development.
    Dzobo K; Ganz C; Thomford NE; Senthebane DA
    OMICS; 2021 Feb; 25(2):81-92. PubMed ID: 33170084
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cancer stem cell targeting: the next generation of cancer therapy and molecular imaging.
    Shigdar S; Lin J; Li Y; Yang CJ; Wei M; Zhus Y; Liu H; Duan W
    Ther Deliv; 2012 Feb; 3(2):227-44. PubMed ID: 22834199
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sustained expression of the RON receptor tyrosine kinase by pancreatic cancer stem cells as a potential targeting moiety for antibody-directed chemotherapeutics.
    Padhye SS; Guin S; Yao HP; Zhou YQ; Zhang R; Wang MH
    Mol Pharm; 2011 Dec; 8(6):2310-9. PubMed ID: 22014215
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cancer stem cells (CSCs), cervical CSCs and targeted therapies.
    Huang R; Rofstad EK
    Oncotarget; 2017 May; 8(21):35351-35367. PubMed ID: 27343550
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
    Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A
    FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.